An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Tandem Diabetes Care (NASDAQ: TNDM) will announce its fourth quarter and full year 2021 results on February 22, 2022, after market close. A conference call and webcast will follow at 4:30 PM ET to discuss the financial and operational highlights. Interested parties can join the call at (855) 427-4396 (toll-free) or (484) 756-4261 (international). An archived version of the webcast will be available for 30 days on their Investor Center website.
Positive
None.
Negative
None.
SAN DIEGO--(BUSINESS WIRE)--
Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, plans to release its fourth quarter and full year 2021 results after the financial markets close on Tuesday, February 22, 2022. The Company will hold a conference call and simultaneous webcast on the same day at 4:30 pm Eastern Time (1:30 pm Pacific Time), to discuss its fourth quarter and full year 2021 financial and operating results.
An archive of the webcast will be available for 30 days following the event on Tandem Diabetes Care’s Investor Center website located at http://investor.tandemdiabetes.com in the “Events & Presentations” section.
About Tandem Diabetes Care, Inc.
Tandem Diabetes Care, Inc. (www.tandemdiabetes.com) is a medical device company dedicated to improving the lives of people with diabetes through relentless innovation and revolutionary customer experience. The Company takes an innovative, user-centric approach to the design, development and commercialization of products for people with diabetes who use insulin. Tandem’s flagship product, the t:slim X2™ insulin pump, is capable of remote software updates using a personal computer and features integrated continuous glucose monitoring, and optional automated insulin delivery technology. Tandem is based in San Diego, California.
